Juhani Knuuti
MD, professor, Turku PET Centre
jknuuti@utu.fi +358 29 450 2345 +358 50 059 2998 Kiinamyllynkatu 4-8 Turku ORCID-tunniste: https://orcid.org/0000-0003-3156-9593 |
Cardiovascular diseases, imaging
Juhani Knuuti’s research has focused on the physiology and pathophysiology, diagnosis and new therapies of coronary artery disease, heart failure and metabolic diseases. The research is also focused on developing and utilizing novel noninvasive imaging methods (PET, SPECT, echocardiography, MRI and CT) that will help to determine the risk and severity of CHD and heart failure and provide guidance for therapy decisions. The recent focus in cardiac research has been on vulnerable plaques, cardiac remodelling and multimodality and hybrid imaging. In metabolic and diabetes research, the focus has been in the interactions between different organs and heart in the pathogenesis and development of the cardiac diseases.
- Lifetime glycaemic exposure predicts reduced coronary vasoreactivity in Type 1 diabetic subjects (2005)
- Diabetic Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Motion detection and correction for dynamic O-15-water myocardial perfusion PET studies (2005)
- European Journal of Nuclear Medicine and Molecular Imaging
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Rosiglitazone improves myocardial glucose uptake in ischemic regions in patients with type 2 diabetes. A 16 week randomised, double-blind, placebo-controlled study (2005)
- Journal of the American College of Cardiology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. A 16 week randomised, double-blind, placebo-controlled study (2005)
- European Heart Journal
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease - A 16-week randomized, double-blind, placebo-controlled study (2005)
- Diabetes
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Rosiglitazone increases the concentration of large, buoyant but not small dense LDL in patients with type 2 diabetes and coronary artery disease, a 16 week randomised, double-blind, placebo-controlled study (2005)
- Diabetes
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Rosiglitazone increases the concentration of large, buoyant but not small dense LDL in patients with type 2 diabetes and coronary artery disease (2005)
- European Heart Journal
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake (2005)
- Diabetes
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - The assessment of glucose appearance rate and hepatic glucose uptake by [18F]fluorodeoxyglucose: validation against 6,6-2H-glucose (2005)
- Diabetologia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - The effect of the Ala(12) allele of the peroxisome proliferator-activated receptor-gamma 2 gene on skeletal muscle glucose uptake depends on obesity: A positron emission tomography study (2005)
- Journal of Clinical Endocrinology and Metabolism
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



